to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Stephen P.A. Fodor is a native of Seattle, Washington. He received his B.S. in Biology and M.S. in Biochemistry from Washington State University and his Ph.D. in Chemistry at Princeton University. From 1986 to 1989, he
was a National Institutes of Health postdoctoral fellow at The University of California, Berkeley, working on time-resolved spectroscopy of bacterial and plant pigments. In 1989 he was recruited to the Affymax Research Institute in Palo
Alto where he spearheaded the effort to develop high-density arrays of biological compounds. Dr. Fodor and colleagues were the first to develop and describe microarray technologies and combinatorial chemistry synthesis. In 1993, Dr. Fodor
co-founded Affymetrix where the chip technology has been used to synthesize many varieties of high density oligonucleotide arrays containing hundreds of thousands of DNA probes. These DNA chips have broad commercial applications and are
now used in many areas of basic and clinical research including the detection of drug resistance mutations in infectious organisms, direct DNA sequence comparison of large segments of the human genome, the monitoring of multiple human
genes for cancer associated mutations, the quantitative and parallel measurement of mRNA expression for thousands of human genes, and the physical and genetic mapping of the human genome. In 2001, Dr. Fodor founded Perlegen, Inc., a new
venture that applied the chip technology on uncovering the basic patterns of human diversity. The adoption of the technology by both commercial and research institutions for these and other applications continues to grow
Thomas J. Fogarty is a specialist whose creative talents have impacted many diverse professional and entrepreneurial arenas. In addition to his teaching responsibilities as Professor of Surgery at Stanford University,
Dr. Fogarty performs numerous cardiac and peripheral vascular surgeries, manages several medical device companies founded upon his product designs, is founder and active Senior Partner in the venture capital firm of Three Arch Partners,
and also finds time to pursue his interest in oenology at the family owned and operated Thomas Fogarty Winery and Vineyards. During the past 40 years he has acquired over 70 surgical patents, including the "industry standard" Fogarty
balloon embolectomy catheter. Patented in 1969, this first balloon catheter for the vascular system was a sophisticated version of the original crude instrument that young Tom Fogarty, then an OR scrub technician, designed in the late
1950's using a surgical glove finger tied to a ureteral catheter. Other commercially successful medical products designed by the Fogarty engineering group include a minimally invasive device for breast cancer diagnosis and therapy, and
also a self-expanding stent-graft used to treat critical aortic aneurysms via a minimally invasive technique. Dr. Fogarty is a past recipient of the Inventor of the Year award given by the San Francisco Patent and Trademark Association, a
four-time recipient of the Distinguished Scientific Presentation award presented by the American College of Surgeons, and was the first recipient to receive the award for "Achievement in Medicine" bestowed by the Santa Clara County Medical
Association. Selected recent awards include the 2000 Lemelson-MIT $500,000 Prize for Invention and Innovation as well as the Association for Advancement of Medical Instrumentation Foundation's Annual Laufman-Greatbatch Prize for inventing
breakthrough medical devices. Later in 200
The launch of a new product is analogous to the birth of a child, necessitating commitment, preparation, the ability to set a date against which to measure progress, and finally delivery, writes the author. Illustrative are scenes from this entrepreneur's introduction of physician-approved videos aimed at educating patients about their diseases.
Many patents are valuable assets and are worth the time and money spent in obtaining them. This topic overview asserts entrepreneurs should undertake an objective analysis of a potential patent's value prior to filing an application to avoid investing in a possibly worthless asset.
Mr. Gifford leads The Foundry in all of its activities, including the identification and early development of new technologies, the formation, staffing and growth of new companies, and serving as a board member of the
new ventures. Most recently, Mr. Gifford was Vice President of Research and Development at Heartport, Inc.. From 1993-1998, he built and led a 62-person team developing a wide variety of novel devices and procedures for Minimally Invasive
Cardiac Surgery that were instrumental in the company's enormously successful public offering in 1996. Heartport's market capitalization at its peak in 1996 reached over $1 billion. In 1992, Mr. Gifford and Professor Dr. Berthold Hoefling
co-founded Bavaria Medizin Technologie (BMT), GmbH, to develop innovative drug delivery catheters and to establish a German source for innovation and production of catheters for Interventional Cardiology. During the two-year period
following the founding of this business, he served in the role of Managing Director of BMT until such time as he transitioned management of the company to a German national. In 1990, Mr. Gifford and John B. Simpson, MD, Ph.D., founded
Cardiovascular Therapeutic Technologies, Inc., a business devoted to the development of innovative local drug delivery catheters for thrombolytic and antiproliferative agents. Eli Lilly and Company acquired this business for its technology
in 1991, and it became the original basis for Guidant's Compass organization. From 1985-1990, Mr. Gifford worked at Devices for Vascular Intervention (DVI), where he was the driving force behind the design of the company's first generation
Peripheral and Coronary atherectomy systems. In addition, during this period he served in various Clinical Research and Marketing capacities. Before joining DVI, Hanson worked in an engineering role at Oximetrix, Inc., working in the field
of intravascular blood gas monitoring
Are bioresorbable stents from one company better than another? Arterial Remodeling Technologies thinks so. The company boasts that its stents offer faster and smoother bioresorption and crack-free expansion.
In medical business news, imaging software firm Riverain Medical hopes to boost sales of a product that helps detect lung cancer. The company’s technology allows radiologists to see behind ribs and clavicles to get a better view of pulmonary nodules. Read more about this company’s promising future.
A treatment for tinnitus is the goal of two Ohio University colleagues who were frustrated by the lack of options for those suffering from this hearing disorder. Read more to find out how this medical device differs from its competitors.
Biotech companies will no longer be able to use wet laboratory space at Cincinnati incubator BioStart in September. However, the organization will continue to offer other services, such as market research, business model assistance and team-building support.
Biotech companies will have a new resource in the Ohio University Innovation Center’s new biotech research and development facility. Read more to learn about what it will offer.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.